
Unlikely duo leads bipartisan Senate bill to expand Right to Try into MDMA and psilocybin
Sens. Cory Booker (D-NJ) and Rand Paul (R-KY) likely don’t share much in common when it comes to policy views, but that didn’t stop the pair from introducing a new bill this week that would alter the controversial Right to Try Act to allow terminally ill patients to access Schedule I drugs after a Phase I trial has been completed.
Building off its predecessor, the bill would skirt around the FDA’s expanded access program and the DEA’s regulations around controlled substances, and allow patients to potentially access Schedule I drugs — like MDMA and psilocybin — much more easily, as the senators say these drugs “have shown exceptional promise in treating a variety of mental health conditions, including suicidal depression, anxiety, and PTSD.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.